ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

被引：217
|
作者：
Cang, Shundong [1 ]
Iragavarapu, Chaitanya [2 ,3 ]
Savooji, John [2 ,3 ]
Song, Yongping [4 ,5 ]
Liu, Delong [4 ,5 ]
机构：
[1] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou 450052, Peoples R China
[2] Westchester Cty Med Ctr, Dept Med, Valhalla, NY 10595 USA
[3] New York Med Coll, Valhalla, NY 10595 USA
[4] Zhengzhou Univ, Henan Canc Hosp, Zhengzhou 450052, Peoples R China
[5] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450052, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2015年 / 8卷
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; IN-VIVO EFFICACY; BISPECIFIC ANTI-CD30/CD16A ANTIBODY; ACUTE MYELOID-LEUKEMIA; BH3 MIMETIC ABT-263; FAMILY PROTEINS; CELL-DEATH; HEMATOLOGICAL MALIGNANCIES; NUCLEAR EXPORT;
D O I：
10.1186/s13045-015-0224-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 ( venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.
引用
收藏
页数：8
相关论文
共 50 条
  • [41] Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
    Vaillant, Francois
    Merino, Delphine
    Lee, Lily
    Breslin, Kelsey
    Pal, Bhupinder
    Ritchie, Matthew E.
    Smyth, Gordon K.
    Christie, Michael
    Phillipson, Louisa J.
    Burns, Christopher J.
    Mann, G. Bruce
    Visvader, Jane E.
    Lindeman, Geoffrey J.
    CANCER CELL, 2013, 24 (01) : 120 - 129
  • [42] Expression of Bcl-2 pro-survival family proteins predicts pharmacological responses to ABT-199, a novel and selective Bcl-2 antagonist, in multiple myeloma models
    Sampath, Deepak
    Punnoose, Elizabeth
    Beghaert, Erwin
    Belmont, Lisa
    Peale, Franklin
    Nguyen Tan
    Chen, Jun
    Darbonne, Walter
    Yue, Peng
    Oeh, Jason
    Lee, Leslie
    Fairbrother, Wayne J.
    Souers, Andrew J.
    Elmore, Steven W.
    Leverson, Joel D.
    CANCER RESEARCH, 2013, 73 (08)
  • [43] Venetoclax (ABT-199), a potent and selective BCL-2 inhibitor, is efficacious in NZB/WF1 mouse model of lupus nephritis and reduces human lymphocyte lifespan in vitro
    Grebe, Kristie
    Perper, Stuart
    O'Connor, Liz
    Schwartz, Annette
    Goess, Christian
    Hartman, Dawna
    Westmoreland, Susan
    Graff, Candace
    Souers, Andrew
    Leverson, Joel
    Elmore, Steven
    Olson, Lisa
    Wang, Lichun
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [44] SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE BCL-2 INHIBITOR VENETOCLAX (ABT-199) IN A PHASE 1 SINGLE AND MULTIPLE ASCENDING DOSE STUDY IN FEMALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Lu, P.
    Fleischmann, R.
    Curtis, C.
    Ignatenko, S.
    Desai, M.
    Wong, S. L.
    Grebe, K. M.
    Zeng, J.
    Medema, J.
    Stolzenbach, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 298 - 298
  • [45] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BCL-2 Inhibitor Venetoclax (ABT-199) in a Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus
    Lu, Peng
    Fleischmann, Roy
    Curtis, Craig
    Ignatenko, Stanislav
    Desai, Monali
    Wong, Shekman L.
    Grebe, Kristie M.
    Zeng, Jiewei
    Medema, Jeroen
    Stolzenbach, James
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [46] SELECTIVE INHIBITION OF BCL-2 IS ACTIVE AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FIRST CLINICAL EXPERIENCE WITH THE BH3-MIMETIC ABT-199
    Roberts, A.
    Davids, M.
    Mahadevan, D.
    Anderson, M.
    Kipps, T.
    Pagel, J.
    Kahl, B.
    Wierda, W.
    Darden, D.
    Nolan, C.
    Xiong, H.
    Huang, D.
    Chyla, B.
    Busman, T.
    Cerri, E.
    Enschede, S.
    Humerickhouse, R.
    Seymour, J.
    HAEMATOLOGICA, 2012, 97 : 219 - 220
  • [47] Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
    Chonghaile, Triona Ni
    Roderick, Justine E.
    Glenfield, Cian
    Ryan, Jeremy
    Sallan, Stephen E.
    Silverman, Lewis B.
    Loh, Mignon L.
    Hunger, Stephen P.
    Wood, Brent
    DeAngelo, Daniel J.
    Stone, Richard
    Harris, Marian
    Gutierrez, Alejandro
    Kelliher, Michelle A.
    Letai, Anthony
    CANCER DISCOVERY, 2014, 4 (09) : 1074 - 1087
  • [48] Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells
    Bodo, Juraj
    Zhao, Xiaoxian
    Durkin, Lisa
    Souers, Andrew J.
    Phillips, Darren C.
    Smith, Mitchell R.
    Hsi, Eric D.
    ONCOTARGET, 2016, 7 (43) : 70000 - 70010
  • [49] Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions
    Weiss, Johanna
    Gajek, Thomas
    Kohler, Bruno Christian
    Haefeli, Walter Emil
    PHARMACEUTICS, 2016, 8 (01)
  • [50] Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199
    Montraveta, Arnau
    Xargay-Torrent, Silvia
    Rosich, Laia
    Lopez-Guerra, Monica
    Roldan, Jocabed
    Rodriguez, Vanina
    Lee-Verges, Eriong
    de Frias, Merce
    Campas, Clara
    Campo, Elias
    Roue, Gael
    Colomer, Dolors
    ONCOTARGET, 2015, 6 (25) : 21159 - 21172
12345